IRTC · Investment summary · as of 29 July 2026
Priced slightly ahead of what the business has demonstrated
Business type: Inflection · scaling but economically observable
The operating path required by today's price is not achievable on the evidence.
At $122.23, IRTC requires a 33% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 23%.
The value rests on an exit multiple of 10.5x and a terminal operating margin of 19%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Named cause: an adverse resolution of the 12 December 2025 DOJ False Claims Act civil investigative demand concerning Zio AT reimbursement claims, and/or a CMS practice-expense revaluation of CPT 93247.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Pre-profit (TTM operating margin -5.2%, Q1-2026 -8.1%) BUT with usable economic evidence: gross margin 70.9% and expanding (66.3%->68.8%->70.9%); identifiable per-test contribution economics ($253.18 national rate against a 29.1% cost of revenue); visible expense scaling (opex +11.1% vs revenue +25.7%; SG&A/revenue 75.6%->68.2%; R&D/revenue 13.6%->10.7%). |
| What do we forecast? | Revenue growth of 23% demonstrated; a terminal operating margin of 19%; an exit multiple of 10.5x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -10.0 percentage points. |
| What is it worth? | Twelve-month target $172.15, +41% from the struck price. Scenario-weighted expected return net of costs +40.8%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
Not determined — no falsifiable operating conditions are on file for this name, so the thesis cannot be reduced to a small number of testable claims
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 29 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
Named cause: an adverse resolution of the 12 December 2025 DOJ False Claims Act civil investigative demand concerning Zio AT reimbursement claims, and/or a CMS practice-expense revaluation of CPT 93247. These are the two named, dated mechanisms, and they are not independent — an FCA finding about how Zio AT reports were prepared and billed would strengthen the case for repricing the code, and the July-2024 483 observation about *"the involvement of the technicians to prepare the Zio ECG reports"* sits at the intersection. Quantified: 93247 is a practice-expense-driven code (7.57 of 7.58 RVUs are PE)
Not determined — no falsifiable invalidation conditions are on file, so this position cannot be risk-monitored
On approach to the $172.15 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Named cause: an adverse resolution of the 12 December 2025 DOJ False Claims Act civil investigative demand concerning Zio AT reimbursement claims, and/or a CMS practice-expense revaluation of CPT 93247. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -10.0 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: named cause: an adverse resolution of the 12 December 2025 DOJ False Claims Act civil investigative demand concerning Zio AT reimbursement claims, and/or a CMS practice-expense revaluation of CPT 93247. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $105.89, which forces an immediate review.